Premium
HIV vaccine development and clinical trials
Author(s) -
Hoff Rodney,
McNamara James,
Fowler MaryGlenn,
McCauley Marybeth
Publication year - 1994
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1994.tb13340.x
Subject(s) - medicine , clinical trial , immunogenicity , hiv vaccine , aids vaccines , pandemic , transmission (telecommunications) , human immunodeficiency virus (hiv) , immunology , immunization , virology , vaccine trial , lentivirus , intensive care medicine , disease , viral disease , covid-19 , infectious disease (medical specialty) , immune system , electrical engineering , engineering
The magnitude of HIV pandemic has made the development of HIV vaccines an urgent biomedical research priority. Although the biologic problems in designing a vaccine for a chronic viral infection like HIV are formidable, there has been encouraging progress. More than a dozen first generation prophylactic HIV vaccine candidates have completed phase I human trials that have established the safety and immunogenicity of these products in adults. A phase II trial of two HIV subunit envelope vaccines in adults at high risk of HIV infection is underway in the United States, and preparations for phase III efficacy trials have begun. Preliminary studies are under way to evaluate the potential application of active and passive immunization for preventing vertical transmission of HIV. Because of the higher rate of HIV transmission and a more abbreviated time course to disease, it may be more efficient to evaluate the efficacy of HIV vaccines in HIV infected pregnant women and their offspring than in adults who are exposed sexually to HIV.